These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 15563249)

  • 1. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.
    De Keyser F; Baeten D; Van den Bosch F; Kruithof E; Verbruggen G; Mielants H; Veys E
    Drugs; 2004; 64(24):2793-811. PubMed ID: 15563249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
    Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
    Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.
    Braun J; Sieper J; Breban M; Collantes-Estevez E; Davis J; Inman R; Marzo-Ortega H; Mielants H
    Ann Rheum Dis; 2002 Dec; 61 Suppl 3(Suppl 3):iii51-60. PubMed ID: 12381511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-alpha therapy in ankylosing spondylitis.
    Wendling D; Toussirot E
    Expert Opin Pharmacother; 2004 Jul; 5(7):1497-507. PubMed ID: 15212600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF-alpha therapy in ankylosing spondylitis.
    De Keyser F; Van den Bosch F; Mielants H
    Cytokine; 2006 Mar; 33(5):294-8. PubMed ID: 16516484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.
    Braun J; van der Heijde D
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1097-109. PubMed ID: 12831346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Spondylarthropathies and anti-TNFalpha drugs].
    Pavy S; Allanore Y; Kahan A
    Rev Med Interne; 2005 Sep; 26(9):717-24. PubMed ID: 16154026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.
    Braun J; Sieper J
    Arthritis Res; 2002; 4(5):307-21. PubMed ID: 12223105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF antagonists for ankylosing spondylitis.
    Drug Ther Bull; 2005 Mar; 43(3):19-22. PubMed ID: 15762384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological therapies in the spondyloarthritides--the current state.
    Braun J; Sieper J
    Rheumatology (Oxford); 2004 Sep; 43(9):1072-84. PubMed ID: 15187239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies].
    Wendling D; Claudepierre P; Lohse A; Toussirot E; Breban M
    Presse Med; 2003 Oct; 32(32):1517-24. PubMed ID: 14534471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumour necrosis factor (TNF)-alpha therapy in undifferentiated spondyloarthropathy.
    Schnarr S; Kuipers JG; Zeidler H
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S126-9. PubMed ID: 12463462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
    Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept: new indication. For ankylosing spondylitis: another option.
    Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.
    Sieper J; Braun J
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii58-61. PubMed ID: 11890656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
    Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
    J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM; Burgos-Vargas R; Laxer RM
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.